Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United Health ProductsUEEC +2.61% Piotroski F-Score is 2 as of Aug. 02, 2026, which is 33% below its 10-year median of 3.00. The stock has 3 warning signs investors should review. Among 800 Medical Devices & Instruments companies, United Health Products ranks worse than 90.25% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
United Health Products has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for United Health Products's Piotroski F-Score or its related term are showing as below:
UEEC'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 3 Max: 6
Current: 2
During the past 13 years, the highest Piotroski F-Score of United Health Products was 6. The lowest was 1. And the median was 3.
United Health Products (OTCPK:UEEC) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
United Health Products Piotroski F-Score Related Terms
United Health Products Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for United Health Products's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UEEC vs FEMY, BNGO, RGNT: Piotroski F-Score Comparison
For the Medical Instruments & Supplies subindustry, United Health Products's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Health Products Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, United Health Products's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where United Health Products's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
United Health Products's current Net Income (TTM) was -1.45.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
United Health Products's current Cash Flow from Operations (TTM) was -1.00.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
United Health Products's return on assets of this year was -13.84761905. United Health Products's return on assets of last year was -13.22746781.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
United Health Products's gearing of this year was 1.47579693. United Health Products's gearing of last year was 6.54937571.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
United Health Products's current ratio of this year was 0.01121451. United Health Products's current ratio of last year was 0.01937984.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
United Health Products's number of shares in issue this year was 258.69. United Health Products's number of shares in issue last year was 254.577.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
United Health Products's gross margin of this year was . United Health Products's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
United Health Products's asset turnover of this year was 0. United Health Products's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
United Health Products has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
United Health Products (UEEC) has a Piotroski F-Score of 2 as of Aug. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on United Health Products and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, United Health Products' Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, United Health Products ranks #722 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 90.2%.
Is United Health Products' Piotroski F-Score too high?
United Health Products' current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. United Health Products' value of 2 is 60% below this industry median. Based on the distribution chart, United Health Products ranks #722 out of 800 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does United Health Products' Piotroski F-Score compare to FEMY and BNGO?
According to the Medical Devices & Instruments industry distribution chart, United Health Products ranks #722 out of 800 companies for Piotroski F-Score. This places United Health Products in the lower half of its industry. The industry median Piotroski F-Score is 5.00. United Health Products' value of 2 is 60% below this benchmark. Historically, United Health Products' own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, United Health Products has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Health Products's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on United Health Products and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Health Products's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Health Products stock overvalued right now?
United Health Products (UEEC) has a current Piotroski F-Score of 2. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 60% below the Medical Devices & Instruments industry median of 5.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For United Health Products (UEEC), the current Piotroski F-Score is 2 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
United Health Products Inc develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Its gauze product, CelluSTAT, is derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. The company are in the process of seeking regulatory approval to sells hemostatic gauze product line into the U.S. Class III and European CE Mark human surgical markets. The company operates as a single operating segment, focusing on the development and commercialization of medical devices, particularly its patented hemostatic gauze, CelluSTAT.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UEEC has been successfully added to your 
